Newly FDA-Cleared Stereotactic System Can be Utilized with Pre-Op MRI or CT
Utilized for neurological procedures including biopsies, catheter placement and electrode introduction, the SmartFrame OR Stereotactic System can be combined with preoperative MRI or CT to ensure optimal placement of devices and instruments.
The Food and Drug Adminstration (FDA) has granted 510(k) clearance for the SmartFrame OR Stereotactic System, which reportedly facilitates optimal preoperative placement of instruments and devices for neurological procedures.
Comprised of the SmartFrame OR and the ClearPointer™ Optical Navigation Wand, the SmartFrame OR Stereotactic System can enhance preoperative planning for electrode introduction, catheter placement and brain biopsy procedures, according to ClearPoint Neuro, the manufacturer of the system. The company noted the SmartFrame OR can be combined with preoperative magnetic resonance imaging (MRI) or computed tomography (CT).
Utilized in combination with the SmartFrame OR and a compatible stereotactic optical navigation system, the ClearPointer Optical Navigation Wand facilitates patient registration and navigation, according to ClearPoint Neuro.
“SmartFrame OR embodies over a decade of accumulated expertise in MRI-guided navigation, now enhanced with the latest OR imaging technology,” said Rob Rubio, a segment leader for neuromodulation at ClearPoint Neuro. “It offers surgeons flexible workflows, including iCT forward projection, enabling precise image-based corrections to achieve sub-millimetric accuracy.”
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
